Literatur – 4. Früher ist nicht zwangsläufig besser
1. Raffle A, Gray M. Screening: evidence and practice. Oxford: Oxford University Press, überarb. Nachdruck, 2009.
2. Sense About Science. Making sense of screening. London: Sense About Science, 2009. Zugänglich unter: www.senseaboutscience.org.
3. Goodman MT, Gurney JG, Smith MA, et al. Sympathetic nervous system tumors. In: Ries LAG, Smith MA, Gurney JG, et al (eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institute, SEER Program. NIH Pub. No.994649. Bethesda, MD, 1999. SEER Pediatric Monograph. Zugänglich unter http://seer.cancer.gov/publications/childhood.
4. Mullassery D, Dominici C, Jesudason EC, et al. Neuroblastoma: contemporary management. Archives of Disease in Childhood – Education and Practice 2009; 94:177–185.
5. Morris JK. Screening for neuroblastoma in children. Journal of Medical Screening 2002; 9: 56.
6. Raffle A, Gray M. op. cit., S. 89–92.
7. Welch HG. Should I be tested for cancer? Maybe not and here’s why. Berkeley and Los Angeles: University of California Press, 2004, S. 77.
8. Cosford PA, Leng GC, Thomas J. Screening for abdominal aortic aneurysm. Cochrane Database of Systematic Reviews, 2007, Issue 2, Art. No.: CD002945.
9. Welch HG. Screening mammography – a long run for a short slide? New England Journal of Medicine 2010; 363: 1276–1278.
10. Heath I. It is not wrong to say no. Why are women told only the benefits of breast screening and none of the possible harms? BMJ 2009; 338: 1534.
11. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD001877.
12. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003373. (keine Änderungen, Update, Issue 3, Juli 2008.)
13. McPherson K. Should we screen for breast cancer? BMJ 2010:340:c3106.
14. Cancer Research UK. Prostate cancer – UK incidence statistics. Aktualisiert am 23. Dezember 2010. http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence.
15. Chapman S, Barratt A, Stockler M. Let sleeping dogs lie? What men should know before getting tested for prostate cancer. Sydney: Sydney University Press, 2010. pdf zugänglich unter: http://ses.library.usyd.edu.au/bitstream/2123/6835/3/Let-sleeping-dogs-lie.pdf.
16. Holmström B, Johansson M, Bergh A, et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009; 339: b3537.
17. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543.
18. Stark JR, Mucci L, Rothman KJ, et al. Prostate cancer screening: the controversy continues. BMJ 2009; 339: b3601.
19. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine 2011; 365: 395–409.
20. Moynihan R. Beware the fortune tellers peddling genetic tests. BMJ 2010; 341:c7233.
21. Thornton H. The screening debates: time for a broader approach? European Journal of Cancer 2003; 39: 1807–1809.
22. Adapted from Wilson JMG, Jungner G. Principles and practice of screening for disease. Public health paper no 34. Geneva: World Health Organization, 1968.
23. COMARE 12th Report: The impact of personally initiated X-ray computed tomography scanning for the health assessment of asymptomatic individuals. Pressemitteilung vom 19. Dezember 2007. www.comare.org.uk/12thReportPressRelease.htm.
24. Department of Health. Better protection for patients having «MOT» scans: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/MediaCentre/Pressreleasesarchive/DH_115243.
25. Food and Drug Administration. Radiation-emitting products: Computed tomography and full-body CT scans – what you need to know: www.fda.gov/radiation-emittingProducts.